Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2023-06-28 Annual Report (ESEF)
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Annual Report and Accounts 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2023-06-28 English
Annual Report and Accounts 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'SYNCONA LIMITED ANNUAL REPORT AND ACCOUNTS 2023'. It contains comprehensive sections typical of an annual report, including a strategic report, governance report, financial statements (consolidated statement of comprehensive income, financial position, cash flows), and auditor's report. It covers the full fiscal year performance and provides detailed financial data, fitting the definition of a 10-K (Annual Report). FY 2023
2023-06-28 English
Publication of 2023 Annual Report & Notice of AGM
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3819 characters) released via RNS (RNS Number: 0924E) on June 28, 2023. The title explicitly states 'Publication of 2023 Annual Report and Notice of Annual General Meeting'. It confirms that the 2023 Annual Report and the Notice of the AGM have been published and filed with the National Storage Mechanism, and provides links to where these full documents can be found. According to Rule 2 ('MENU VS MEAL' rule), when a document announces the publication of a full report (like an Annual Report or AGM notice) rather than containing the full report itself, it should be classified as a Report Publication Announcement (RPA). The document also mentions the AGM details, which could suggest AGM-R, but the primary function here is announcing the availability of multiple documents, making RPA the most accurate fit for this specific announcement type.
2023-06-28 English
Final Results
Earnings Release Classification · 95% confidence The document is titled 'Full Year Results for the 12 months ended 31 March 2023' and contains detailed financial performance metrics, including net assets, NAV returns, and portfolio valuations. It is a comprehensive summary of the company's annual financial performance and strategic outlook, which fits the definition of an Earnings Release (ER) as it provides the initial announcement of yearly financial results with key highlights, rather than the full, audited Annual Report (10-K) document itself. FY 2023
2023-06-15 English
Syncona launches new gene therapy company Beacon
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement released via the RNS (Regulatory News Service) system, indicated by the 'RNS Number : 3233C' header. The content details the launch of a new company, Beacon Therapeutics, funded by Syncona Limited, including specifics about financing (£96 million Series A), strategic rationale, management appointments, and pipeline updates. This structure—a formal press release announcing a significant corporate event (creation of a new company and financing)—is characteristic of a general regulatory announcement. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific proxy/insider filing, the most appropriate classification is the general regulatory announcement category, RNS, especially given the RNS header.
2023-06-12 English
Quell signs collaboration with AstraZeneca
Regulatory Filings Classification · 99% confidence The document begins with an RNS Number and a date, indicating it is a regulatory announcement. The content describes a significant business event: a collaboration and license agreement between Quell Therapeutics (a company Syncona is invested in) and AstraZeneca regarding cell therapy development. This type of announcement, detailing a major partnership, financing component ($85 million upfront), and potential future payments, is characteristic of a corporate transaction or significant business update. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it details a major corporate transaction (collaboration/licensing agreement) that involves significant financial terms and strategic partnership, it best fits the 'Capital/Financing Update' (CAP) category, as it involves a large upfront payment and equity investment component, or potentially 'Regulatory Filings' (RNS) as a general announcement. However, given the focus on the financial structure of the deal ($85M upfront, equity investment, $2B potential payments), CAP is a strong fit. Alternatively, since it is distributed via RNS and details a major corporate event without being a specific financial statement, RNS is also plausible. Given the explicit mention of upfront cash and equity investment related to a deal, I will classify it as a Capital/Financing Update (CAP), as this is more specific than the general RNS fallback, although RNS is also highly relevant due to the distribution method.
2023-06-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.